Skyhawk Therapeutics Reports Interim Phase 1 Results for Huntington's Treatment SKY-0515

Skyhawk Therapeutics released promising nine-month interim results from its Phase 1 clinical trial of SKY-0515, a potential treatment for Huntington's disease. Findings show a mean improvement in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) of +0.64 points, contrasting with the expected decline of -0.73 points in untreated patients. The treatment demonstrated a 62% reduction of mHTT protein in blood at the 9mg dose and a 26% reduction of PMS1 mRNA. SKY-0515 also showed excellent safety and central nervous system exposure.

Additionally, the Phase 2/3 FALCON-HD trial has expanded globally, with over 90 patients already dosed. The first-in-human Phase 1 trial is designed to evaluate safety and efficacy in early-stage patients. Skyhawk plans to further explore SKY-0515's potential as a disease-modifying therapy for Huntington's.